SPX4,071.70-4.87 -0.12%
DIA344.74+0.33 0.10%
IXIC11,461.50-20.95 -0.18%

Chardan Capital Maintains Buy on Pear Therapeutics, Lowers Price Target to $8

Benzinga · 11/15/2022 12:21
Chardan Capital analyst Keay Nakae maintains Pear Therapeutics (NASDAQ:PEAR) with a Buy and lowers the price target from $9 to $8.